We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01724580
Expanded Access Status : No longer available
First Posted : November 12, 2012
Last Update Posted : January 18, 2023
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Condition or disease Intervention/treatment
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE) Juvenile Dermatomyositis (JDM) Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI) Aicardi-Goutières Syndrome (AGS) Drug: Baricitinib

Layout table for study information
Study Type : Expanded Access
Official Title: Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis

Intervention Details:
  • Drug: Baricitinib
    Administered orally
    Other Names:
    • LY3009104
    • INCB 028050

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Are ≥17.5 months of age (or are ≥6 months of age with Aicardi-Goutières Syndrome [AGS]). Participants younger than 17.5 months of age can be considered for enrollment after discussion with the sponsor.
  • Have systemic signs and symptoms of inflammation as manifested by the presence of two or more of the following symptoms: rash, fever, musculoskeletal pain, headache, fatigue, weakness, respiratory/breathing symptoms, or ulcers/ischemic lesions.
  • Have an average daily Diary Score of ≥0.5 (CANDLE Diary; used also for CANDLE-related conditions, AGS Diary) or ≥1.0 (SAVI) or ≥1.0 exclusive of headache and fever symptoms (JDM Diary) assessed over at least 2 weeks prior to entry, if available. Otherwise, participants can complete the diary after study consent is signed during the screening period and meet the inclusion criteria for enrollment into the study.
  • Are ≥8.5 kilogram (kg) in body weight. Participants weighing less than 8.5 kg can be considered for enrollment after discussion with the sponsor.
  • Have been previously treated with at least 1 biologic therapy and, in the opinion of the investigator, did not respond or are no longer responding to therapy. If the participant has been diagnosed with CANDLE, Nakajo-Nishimura Syndrome (NNS), SAVI, AGS, or an equivalent syndrome, the need for previous biologic therapy is not required.
  • Require treatment with oral corticosteroids (≥0.15 milligrams per kilogram per day [mg/kg/d] of prednisone or its equivalent) for control of systemic signs and symptoms of their chronic inflammatory disease for at least 2 weeks prior to study entry, or in the opinion of the investigator, have failed an adequate course of steroids. Treatment with or failure of treatment with steroids is not required for participants with AGS or a confirmed genetic diagnosis of CANDLE or SAVI.
  • Have had previous documented elevations in acute-phase reactants (for example, high sensitivity C-reactive protein) considered to be the result of the inflammatory disease (participants with CANDLE or CANDLE-related conditions only).
  • Have the ability to provide informed consent or have legal representative who is willing and able to provide written informed consent, provided that assent is obtained from participants at an age-appropriate level.

Exclusion Criteria:

  • Have received an immunosuppressive biologic agent/monoclonal antibody within 4 half-lives prior to entry, for example, anakinra (4 half-lives=18 hours); etanercept (4 half-lives=18 days); infliximab; adalimumab (4 half-lives=36 days); use of intravenous immune globulin (IVIg) is permitted.
  • Are pregnant or nursing at the time of entry.
  • Are females of childbearing potential (women >12 or who have had at least 1 menstrual period regardless of age) who are sexually active and who do not agree to use 2 forms of highly effective methods of birth control or remain abstinent during the study and for at least 28 days following the last dose of investigational product.
  • Are sexually active males who do not agree to use 2 forms of highly effective birth control with female partners of childbearing potential or remain abstinent during the study and for at least 28 days following the last dose of investigational product.
  • Have had symptomatic herpes zoster infection within 12 weeks prior to entry or during the screening period.
  • Have a history of disseminated/complicated herpes zoster (for example, multidermatomal involvement, ophthalmic zoster, central nervous system [CNS] involvement, postherpetic neuralgia).
  • Have evidence of active infection, at the time of entry or during the screening period, that in the opinion of the investigator, would pose an unacceptable risk for participating in the study.
  • Have a history of active hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV).
  • Have documented high titer autoantibodies suggestive clinically of autoimmune diseases other than severe JDM.
  • Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study.
  • Have had a serious systemic or local infection (including an infectious mononucleosis-like illness or herpes zoster) within 12 weeks prior to entry or during the screening period.
  • Have been exposed to a live vaccine within 12 weeks prior to entry or are expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study.

Note: Investigators should review the vaccination status of the participants and follow the local guidelines for vaccination with nonlive vaccines intended to prevent infectious disease prior to entering participants into the study.

  • Have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB.
  • Have a serious and/or unstable illness that, in the opinion of the investigator, poses an unacceptable risk for the participant's participation in the study.
  • Have an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of <40 milliliters/minute/1.73 per square meter.
  • Have or have had a history of lymphoproliferative disease; or signs or symptoms suggestive of possible lymphoproliferative disease, or active primary or recurrent malignant disease; or been in remission from clinically significant malignancy for <5 years.

Note: Participants with resolved cervical dysplasia, or no more than 3 successfully treated basal-cell carcinoma of the skin, may participate in this study.

  • Have a history of chronic alcohol abuse or intravenous (IV) drug abuse within the 2 years prior to entry.
  • Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures.
  • Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving an investigational product or non-approved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01724580

Layout table for location information
United States, Maryland
Translational Autoinflammatory Disease (TADS)
Bethesda, Maryland, United States, 20892
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United Kingdom
Great Ormond Street Hospital
London, United Kingdom, WC1N 1EH
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01724580    
Other Study ID Numbers: 14559
I4V-MC-JAGA ( Other Identifier: Eli Lilly and Company )
First Posted: November 12, 2012    Key Record Dates
Last Update Posted: January 18, 2023
Last Verified: January 15, 2023
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Pathologic Processes
Skin Diseases, Metabolic
Lipid Metabolism Disorders
Metabolic Diseases
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Body Temperature Changes
Heat Stress Disorders
Wounds and Injuries